Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessing the sensitivity and acceptability of the Royal Marsden Palliative Care Referral "Triggers" Tool for outpatients with cancer.
Kamal L, Kano Y, Stevens AM, Mohammed K, Pattison N, Perkins M, Popat S, Benson C, Minton O, Laverty D, Wiseman T, Mayland CR, Gough N, Williams C, Want J, Tweddle A, Wood J, Droney J. Kamal L, et al. Among authors: popat s. Support Care Cancer. 2024 Oct 16;32(11):730. doi: 10.1007/s00520-024-08921-5. Support Care Cancer. 2024. PMID: 39412528 Free PMC article.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. Among authors: popat s. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.
Houda I, Dickhoff C, Uyl-de Groot CA, Reguart N, Provencio M, Levy A, Dziadziuszko R, Pompili C, Di Maio M, Thomas M, Brunelli A, Popat S, Senan S, Bahce I. Houda I, et al. Among authors: popat s. Lancet Reg Health Eur. 2024 Mar 4;38:100840. doi: 10.1016/j.lanepe.2024.100840. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476748 Free PMC article. Review.
Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective.
Houda I, Dickhoff C, Uyl-de Groot CA, Damhuis RAM, Reguart N, Provencio M, Levy A, Dziadziuszko R, Pompili C, Di Maio M, Thomas M, Brunelli A, Popat S, Senan S, Bahce I. Houda I, et al. Among authors: popat s. Lancet Reg Health Eur. 2024 Mar 1;38:100841. doi: 10.1016/j.lanepe.2024.100841. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476749 Free PMC article. Review.
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
de Jager VD, Timens W, Bayle A, Botling J, Brcic L, Büttner R, Fernandes MGO, Havel L, Hochmair M, Hofman P, Janssens A, van Kempen L, Kern I, Machado JC, Mohorčič K, Popat S, Ryška A, Wolf J, Schuuring E, van der Wekken AJ. de Jager VD, et al. Among authors: popat s. Lancet Reg Health Eur. 2024 Mar 1;38:100839. doi: 10.1016/j.lanepe.2024.100839. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38476751 Free PMC article. Review.
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).
Spira A, Cho BC, Felip E, Garon EB, Goto K, Johnson M, Leighl N, Passaro A, Planchard D, Popat S, Yang JC, Lu X, Jiang Y, Huang J, Lam M, Kowanetz M, Wang S, Le J, Hsu JY, Zhou CC. Spira A, et al. Among authors: popat s. Lung Cancer. 2024 Dec 28;199:108066. doi: 10.1016/j.lungcan.2024.108066. Online ahead of print. Lung Cancer. 2024. PMID: 39764938 Review. No abstract available.
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer.
Houda I, Bahce I, Dickhoff C, Kroese TE, Kroeze SGC, Mariolo AV, Tagliamento M, Moliner L, Brandão M, Pretzenbacher Y, Edwards J, Opitz I, Brunelli A, Guckenberger M, van Schil PE, Popat S, Blum T, Faivre-Finn C, de Ruysscher D, Remon J, Berghmans T, Dingemans AC, Besse B, Hendriks LEL. Houda I, et al. Among authors: popat s. Lung Cancer. 2024 Dec 15;199:108061. doi: 10.1016/j.lungcan.2024.108061. Online ahead of print. Lung Cancer. 2024. PMID: 39705827 Free article.
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
Popat S, Januszewski A, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, Roitt S, Morris C, Ngai Y, Hughes L, Hackshaw A, Wilson W. Popat S, et al. Br J Cancer. 2024 Dec 5. doi: 10.1038/s41416-024-02901-6. Online ahead of print. Br J Cancer. 2024. PMID: 39639088
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer.
Lee SH, Menis J, Kim TM, Kim HR, Zhou C, Kurniawati SA, Prabhash K, Hayashi H, Lee DD, Imasa MS, Teh YL, Yang JC, Reungwetwattana T, Sriuranpong V, Wu CE, Ang Y, Sabando M, Thiagarajan M, Mizugaki H, Noronha V, Yulianti M, Zhang L, Smyth E, Yoshino T, Park JO, Pentheroudakis G, Park S, Peters S, Ahn JB, Popat S. Lee SH, et al. Among authors: popat s. ESMO Open. 2024 Dec;9(12):103996. doi: 10.1016/j.esmoop.2024.103996. Epub 2024 Nov 29. ESMO Open. 2024. PMID: 39615406 Free PMC article.
422 results